237 related articles for article (PubMed ID: 36529434)
1. Effect of Extent of Resection on Survival of Patients with Glioblastoma, IDH-Wild-Type, WHO Grade 4 (WHO 2021): Systematic Review and Meta-Analysis.
Jusue-Torres I; Lee J; Germanwala AV; Burns TC; Parney IF
World Neurosurg; 2023 Mar; 171():e524-e532. PubMed ID: 36529434
[TBL] [Abstract][Full Text] [Related]
2. Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis.
Mier-García JF; Ospina-Santa S; Orozco-Mera J; Ma R; Plaha P
J Neurooncol; 2023 Aug; 164(1):31-41. PubMed ID: 37561356
[TBL] [Abstract][Full Text] [Related]
3. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma.
Vivas-Buitrago T; Domingo RA; Tripathi S; De Biase G; Brown D; Akinduro OO; Ramos-Fresnedo A; Sabsevitz DS; Bendok BR; Sherman W; Parney IF; Jentoft ME; Middlebrooks EH; Meyer FB; Chaichana KL; Quinones-Hinojosa A
J Neurosurg; 2022 Jan; 136(1):1-8. PubMed ID: 34087795
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
[TBL] [Abstract][Full Text] [Related]
5. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
[TBL] [Abstract][Full Text] [Related]
6. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
7. Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis.
Brown TJ; Brennan MC; Li M; Church EW; Brandmeir NJ; Rakszawski KL; Patel AS; Rizk EB; Suki D; Sawaya R; Glantz M
JAMA Oncol; 2016 Nov; 2(11):1460-1469. PubMed ID: 27310651
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma.
Jackson C; Choi J; Khalafallah AM; Price C; Bettegowda C; Lim M; Gallia G; Weingart J; Brem H; Mukherjee D
J Neurooncol; 2020 Jul; 148(3):419-431. PubMed ID: 32562247
[TBL] [Abstract][Full Text] [Related]
9. Interaction Between the Contributions of Tumor Location, Tumor Grade, and Patient Age to the Survival Benefit Associated with Gross Total Resection.
Carroll KT; Bryant AK; Hirshman B; Alattar AA; Joshi R; Gabel B; Carter BS; Harismendy O; Vaida F; Chen CC
World Neurosurg; 2018 Mar; 111():e790-e798. PubMed ID: 29309983
[TBL] [Abstract][Full Text] [Related]
10. Optimal extent of resection for glioblastoma according to site, extension, and size: a population-based study in the temozolomide era.
Kim YJ; Lee DJ; Park CK; Kim IA
Neurosurg Rev; 2019 Dec; 42(4):937-950. PubMed ID: 30612289
[TBL] [Abstract][Full Text] [Related]
11. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas.
McGirt MJ; Chaichana KL; Attenello FJ; Weingart JD; Than K; Burger PC; Olivi A; Brem H; Quinoñes-Hinojosa A
Neurosurgery; 2008 Oct; 63(4):700-7; author reply 707-8. PubMed ID: 18981880
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era.
Tom MC; Varra V; Leyrer CM; Park DY; Chao ST; Yu JS; Suh JH; Reddy CA; Balagamwala EH; Broughman JR; Kotagal KA; Vogelbaum MA; Barnett GH; Ahluwalia MS; Peereboom DM; Prayson RA; Stevens GHJ; Murphy ES
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1099-1105. PubMed ID: 31022510
[TBL] [Abstract][Full Text] [Related]
13. Biopsy Versus Subtotal Versus Gross Total Resection in Patients with Low-Grade Glioma: A Systematic Review and Meta-Analysis.
Yang K; Nath S; Koziarz A; Badhiwala JH; Ghayur H; Sourour M; Catana D; Nassiri F; Alotaibi MB; Kameda-Smith M; Manoranjan B; Aref MH; Mansouri A; Singh S; Almenawer SA
World Neurosurg; 2018 Dec; 120():e762-e775. PubMed ID: 30172972
[TBL] [Abstract][Full Text] [Related]
14. Effect of Gross Total Resection in World Health Organization Grade II Astrocytomas: SEER-Based Survival Analysis.
Schupper AJ; Hirshman BR; Carroll KT; Ali MA; Carter BS; Chen CC
World Neurosurg; 2017 Jul; 103():741-747. PubMed ID: 28419878
[TBL] [Abstract][Full Text] [Related]
15. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
Drexler R; Schüller U; Eckhardt A; Filipski K; Hartung TI; Harter PN; Divé I; Forster MT; Czabanka M; Jelgersma C; Onken J; Vajkoczy P; Capper D; Siewert C; Sauvigny T; Lamszus K; Westphal M; Dührsen L; Ricklefs FL
Neuro Oncol; 2023 Feb; 25(2):315-325. PubMed ID: 35868257
[TBL] [Abstract][Full Text] [Related]
17. Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis.
Almenawer SA; Badhiwala JH; Alhazzani W; Greenspoon J; Farrokhyar F; Yarascavitch B; Algird A; Kachur E; Cenic A; Sharieff W; Klurfan P; Gunnarsson T; Ajani O; Reddy K; Singh SK; Murty NK
Neuro Oncol; 2015 Jun; 17(6):868-81. PubMed ID: 25556920
[TBL] [Abstract][Full Text] [Related]
18. Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults: An Observational Study.
Pallud J; Huberfeld G; Dezamis E; Peeters S; Moiraghi A; Gavaret M; Guinard E; Dhermain F; Varlet P; Oppenheim C; Chrétien F; Roux A; Zanello M
Neurology; 2022 Jan; 98(2):e125-e140. PubMed ID: 34675100
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
McGirt MJ; Chaichana KL; Gathinji M; Attenello FJ; Than K; Olivi A; Weingart JD; Brem H; Quiñones-Hinojosa AR
J Neurosurg; 2009 Jan; 110(1):156-62. PubMed ID: 18847342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
